Next-generation sequencing (NGS) is rapidly redefining how hematologic malignancies are diagnosed, stratified and monitored. Yet many labs still rely on fragmented single-gene or send-out testing, delaying results and limiting the clinical picture available to hematologists.

Join Professor and Senior Physician in Clinical Genetics Richard Rosenquist Brandell Karolinska Institutet & Director of Genomic Medicine Sweden for an in-depth look at how comprehensive, local NGS including whole-genome and transcriptome sequencing (WGTS), is becoming a new standard of care in acute leukemias and lymphoid malignancies. Prof. Rosenquist will share practical lessons, guideline evolution, and a clear-eyed view of what clinical laboratories should consider today when planning their NGS journey .

Learning Objectives:

• Understand the current role of NGS including targeted panels and WGTS in the diagnosis, classification and monitoring of hematologic malignancies.

• Genomic Medicine Sweden) are implementing NGS at scale, and what this means for individual labs planning the transition from send-out or single-gene testing to in-house workflows.

• Gain evidence-based perspectives on how NGS-driven diagnostics translate into better risk stratification, improved patient outcomes, and stronger alignment with evolving international guidelines (ELN, WHO-HAEM5, ICC).

• Identify technical and regulatory considerations for bringing decentralised in-house NGS testing into clinical practice.

      Register Here     

Newsletters

Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.

I have read and understand the Privacy Notice*

Subscribe